Citations

Mayo Clinic

Showing 10 of 108585 citations.

The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population‐based to a more “personalized” approach to cancer staging
Amin, Mahul B. , Greene, Frederick L. , Edge, Stephen B. , Compton, Carolyn C. , Gershenwald, Jeffrey E., Brookland, Robert K., Meyer, Laura, Gress, Donna M., Byrd, David R. , Winchester, David P., Gershenwald, Jeffrey E.

CA: A Cancer Journal for Clinicians | January 17, 2017 | Volume: 67 | Issue: 2 | Pages: 93-99

10.3322/caac.21388 | PMID 28094848 Get It

Abstract The American Joint Committee on Cancer (AJCC) staging manual has become the benchmark for classifying patients with cancer, defining prognosis, and determining the best treatment approaches. Many view the primary role of the tumor, lymph node, metastasis (TNM) system as that of a standardized classification system for evaluating cancer at a population level in terms of the extent of disease, both at initial presentation and after surgical treatment, and the overall impact of improvements in cancer treatment. The rapid evolution of knowledge in cancer biology and the discovery and validation of biologic factors that predict cancer outcome and response to treatment with better accuracy have led some cancer experts to question the utility of a TNM‐based approach in clinical care at an individualized patient level. In the Eighth Edition of the AJCC Cancer Staging Manual , the goal of including relevant, nonanatomic (including molecular) factors has been foremost, although changes are made only when there is strong evidence for inclusion. The editorial board viewed this iteration as a proactive effort to continue to build the important bridge from a “population‐based” to a more “personalized” approach to patient classification, one that forms the conceptual framework and foundation of cancer staging in the era of precision molecular oncology. The AJCC promulgates best staging practices through each new edition in an effort to provide cancer care providers with a powerful, knowledge‐based resource for the battle against cancer. In this commentary, the authors highlight the overall organizational and structural changes as well as “what's new” in the Eighth Edition. It is hoped that this information will provide the reader with a better understanding of the rationale behind the aggregate proposed changes and the exciting developments in the upcoming edition. CA Cancer J Clin 2017;67:93–99. © 2017 American Cancer Society.
Subacute demyelinating polyradiculoneuropathy complicating Epstein–Barr virus infection in GATA2 haploinsufficiency
Kazamel, Mohamed , Klein, Christopher J. , Benarroch, Eduardo E. , Patnaik, Mrinal M. , Tracy, Jennifer A., Klein, Christopher J

Muscle & Nerve | January 17, 2017 | Volume: 57 | Issue: 1 | Pages: 150-156

10.1002/mus.25581 | PMID 28093780 Get It

ABSTRACTIntroduction: Autosomal dominant haploinsufficiency of GATA2 causes monocytopenia and natural killer cell lymphopenia, resulting in predisposition to mycobacterial, fungal, and viral infections. Methods: Herein we report on the clinical, serologic, electrophysiologic, and pathologic evaluations of a 29‐year‐old woman with GATA2 haploinsufficiency and active Epstein–Barr virus (EBV) infection complicated by subacute painful neuropathy. Results: Nerve conduction and electromyography studies showed predominantly demyelinating sensorimotor polyradiculoneuropathy. Lumbar spine MRI showed thickening and enhancement of the cauda equina nerve roots. Serum and cerebrospinal fluid anti‐IgG and IgM EBV capsid and nucleic acid antibodies were positive. Sural nerve biopsy showed microvasculitis and an increased frequency of fibers with segmental demyelination. Intravenous immunoglobulin and steroids improved the patient's neuropathy. Conclusion: GATA2 mutation–related immunodeficiency may predispose to EBV‐associated subacute demyelinating polyradiculoneuropathy by both viral susceptibility and immune dysregulation. In patients who present in this manner, immunodeficiency syndromes should be considered when lymphomatous infiltration is excluded. Immunotherapy can be helpful. Muscle Nerve 57: 150–156, 2018
A message from the “True” ground
Rubin, Devon I., Kincaid, John C.

Muscle & Nerve | January 17, 2017 | Volume: 55 | Issue: 6 | Pages: 928-929

10.1002/mus.25579 | PMID 28093776 Get It

Natural history of pure autonomic failure: A United States prospective cohort
Kaufmann, Horacio , Norcliffe‐Kaufmann, Lucy , Palma, Jose‐Alberto , Low, Phillip A. , Peltier, Amanda , Shibao, Cyndia A., Robertson, David, Kaufmann, Horacio , Palma, Jose-Alberto , Biaggioni, Italo , Singer, Wolfgang , Goldstein, David S. , Gibbons, Christopher H. , Freeman, Roy L.

Annals of Neurology | January 17, 2017 | Volume: 81 | Issue: 2 | Pages: 287-297

10.1002/ana.24877 | PMID 28093795 Get It

ObjectiveTo define the clinical features and biomarkers that predict which patients with pure autonomic failure will develop Parkinson disease, dementia with Lewy bodies, or multiple system atrophy.MethodsOne hundred patients who presented with pure autonomic failure were recruited at 5 medical centers in the United States. Seventy‐four patients agreed to be followed prospectively. Patients underwent clinical evaluations including neurological rating scales, sleep questionnaires, smell test, and sympathetic and parasympathetic cardiovascular autonomic function tests.ResultsAt enrollment, patients were 68 ± 12 years old (median ± interquartile range) and had had autonomic failure for 5 ± 7 years. Within 4 years of follow‐up, 25 of 74 subjects (34%) developed dementia with Lewy bodies (n = 13), Parkinson disease (n = 6), or multiple system atrophy (n = 6). The presence of probable rapid eye movement (REM) sleep behavior disorder was strongly associated with the development of a manifest central nervous system (CNS) synucleinopathy (odds ratio = 7.1). Patients who phenoconverted to multiple system atrophy had younger age at onset of autonomic failure, severe bladder/bowel dysfunction, preserved olfaction, and a cardiac chronotropic response upon tilt > 10 beats per minute. Those who phenoconverted to Parkinson disease or dementia with Lewy bodies had decreased olfaction, a lesser chronotropic response to tilt, and a longer duration of illness. The small group of patients retaining the pure autonomic failure phenotype had very low plasma norepinephrine levels, slow resting heart rate, no REM sleep behavior disorder, and preserved smell.InterpretationPatients presenting with pure autonomic failure are at high risk of phenoconverting to a manifest CNS synucleinopathy. Specific clinical features predict future diagnosis. Ann Neurol 2017;81:287–297
Angioplasty of an Idiopathic Intracranial Arterial Stenosis
Kallmes, David F. , Cloft, Harry J. , Layton, Kennith F.

Interventional Neuroradiology | January 17, 2017 | Volume: 12 | Issue: 4 | Pages: 307-311

10.1177/159101990601200403 | PMID 20569587 Get It

Treatment of symptomatic intracranial atherosclerotic stenosis usually involves maximizing medical therapy. In patients with medically refractory symptoms despite maximum pharmacologic therapy, intracranial angioplasty and/or stenting has become an accepted treatment option. The use of percutaneous transluminal angioplasty (PTA) for idiopathic intracranial stenoses has not been reported to date. We describe a case of idiopathic intracranial stenosis which was refractory to medical therapy and was successfully treated with percutaneous transluminal angioplasty. The presenting symptoms included multiple episodes of aphasia and right-sided weakness as well as a left basal ganglia infarct. The patient underwent treatment with two intracranial angioplasty procedures. There was a recurrence of the stenosis and symptoms following the first procedure. However, after a second treatment with a slightly larger balloon, flow in the MCA normalized. Furthermore, the symptoms attributed to her MCA stenosis had essentially resolved. This case suggests that patients with medically refractory idiopathic intracranial stenosis can be successfully treated with percutaneous transluminal angioplasty.
Novel synaptobrevin‐1 mutation causes fatal congenital myasthenic syndrome
Shen, Xin‐Ming , Scola, Rosana Hermínia , Lorenzoni, Paulo José , Brengman, Joan M., Selcen, Duygu , Engel, Andrew G. , Brengman, Joan, Kay, Cláudia Suemi Kamoi , Werneck, Lineu César

Annals of Clinical and Translational Neurology | January 17, 2017 | Volume: 4 | Issue: 2 | Pages: 130-138

10.1002/acn3.387 | PMID 28168212 Get It

AbstractObjectiveTo identify the molecular basis and elucidate the pathogenesis of a fatal congenital myasthenic syndrome.MethodsWe performed clinical electrophysiology studies, exome and Sanger sequencing, and analyzed functional consequences of the identified mutation.ResultsClinical electrophysiology studies of the patient revealed several‐fold potentiation of the evoked muscle action potential by high frequency nerve stimulation pointing to a presynaptic defect. Exome sequencing identified a homozygous c.340delA frameshift mutation in synaptobrevin 1 (SYB1), one of the three SNARE proteins essential for synaptic vesicle exocytosis. Analysis of both human spinal cord gray matter and normal human muscle revealed expression of the SYB1A and SYB1D isoforms, predicting expression of one or both isoforms in the motor nerve terminal. The identified mutation elongates the intravesicular C‐terminus of the A isoform from 5 to 71, and of the D isoform from 4 to 31 residues. Transfection of either mutant isoform into bovine chromaffin cells markedly reduces depolarization‐evoked exocytosis, and transfection of either mutant isoform into HEK cells significantly decreases expression of either mutant compared to wild type.InterpretationThe mutation is pathogenic because elongation of the intravesicular C‐terminus of the A and D isoforms increases the energy required to move their C‐terminus into the synaptic vesicle membrane, a key step for fusion of the synaptic vesicle with the presynaptic membrane, and because it is predicted to reduce expression of either isoform in the nerve terminal.
Interferon β-1b: latest published results, 1995
Noseworthy, John H.

Multiple Sclerosis Journal | January 16, 2017 | Volume: 1 | Issue: 6 | Pages: 313-316

10.1177/135245859600100603 | PMID 9345406 Get It

Interferon β-1b (Betaseron) has been shown in a randomized, double-blind, placebo-controlled study to reduce relapse rate, relapse severity and MRI progression in patients with relapsing-remitting MS. The recently published Betaseron extension trial and studies from the National Institutes of Health provide additional evidence suggesting an important treatment effect The major new findings from these studies are reviewed in this paper. Other findings from these recent studies merit attention, however. Specifically, neutralizing antibody formation was seen in 38% of patients receiving high-dose Betaseron at 3 years. With the development of these antibodies, there was no longer clinical evidence that the drug remained effective. This observation must be considered carefully when initiating Betaseron therapy. The Betaseron trial suggests that MRI is an imperfect predictor of clinical disease activity. Of particular interest was the finding that patients receiving low-dose Betaseron developed ‘confirmed treatment failure’ sooner than placebo-treated patients, despite a clear treatment benefit on MRI-detected evidence of subclinical disease activity.
Chemotherapy can induce weight normalization of morbidly obese mice despite undiminished ingestion of high fat diet
Myers, Cheryl , Hoelzinger, Dominique B. , Truong, Tiffany N. , Chew, Lindsey A. , Myles, Arpita, Chaudhuri, Leena, Egan, Jan B. , Liu, Jun , Gendler, Sandra , Cohen, Peter A. , Myers, Cheryl E, Gendler, Sandra J, Truong, Tiffany N., Liu, Jun , Chew, Lindsey A , Myers, Cheryl E

Oncotarget | January 16, 2017 | Volume: 8 | Issue: 3 | Pages: 5426-5438

10.18632/oncotarget.14576 | PMID 28076839 Get It

Faculty Opinions recommendation of Is nonabsorbable nasal packing after septoplasty essential? A meta-analysis.
Ghorab, Saba , Lal, Devyani

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | January 16, 2017 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.727054856.793526886 Get It

Endoscopic ultrasound-guided fine needle aspiration cytology of metastatic renal cell carcinoma to the pancreas: A multi-center experience
Pannala, Rahul , Hallberg-Wallace, Karyn M., Smith, Amber , Zarka, Matthew A., Reynolds, Jordan , Zarka, Matthew, Chen, Longwen , Hallberg-Wallace, Karyn M., Nassar, Aziza , Zhang, Jun , Reynolds, Jordan P

CytoJournal | January 16, 2017 | Volume: 13 | Issue: No issue available | Pages: 24

10.4103/1742-6413.192191 | PMID 27761149 Get It

Introduction: The increasing use of endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) cytology to examine pancreatic neoplasms has led to an increase in the diagnosis of metastases to the pancreas. Renal cell carcinoma (RCC) is the most common metastasis to the pancreas. Our study examines 33 cases of metastatic RCC to the pancreas sampled by EUS-FNA from four large tertiary care hospitals. Materials and Methods: We searched the cytopathology database for RCC metastatic to the pancreas diagnosed by EUS-FNA from January 2005 to January 2015. Patient age, history of RCC, nephrectomy history, follow-up postnephrectomy, radiological impression, and EUS-FNA cytologic diagnosis were reviewed. Results: Thirty-three patients were identified. The average age was 67.5 years (range, 49–84 years). Thirty-two patients had a previous documented history of RCC. One patient had the diagnosis of pancreatic metastasis at the same time of the kidney biopsy. Thirty-one patients had been treated with nephrectomy. Twenty-seven patients were being monitored annually by computed tomography or magnetic resonance imaging. Twenty-five patients had multiple masses by imaging, but 8 patients had a single mass in the pancreas at the time of EUS-FNA. EUS-FNA of 20 cases showed classic morphology of RCC. Thirteen cases had either “atypical” clinical-radiologic features or morphologic overlaps with primary pancreatic neoplasms or other neoplasms. Cell blocks were made on all 13 cases and immunochemical stains confirmed the diagnosis. Conclusions: EUS-FNA cytology is useful for the diagnosis of metastatic RCC to the pancreas. Cytomorphology can be aided with patient history, imaging analyses, cell blocks, and immunochemical stains.